Investors.oculis.com
Oculis Opens New Offices in the US and Expands its US Team by
WebOculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team strengthened by US-based hires, including Dr. Fang Li as Senior Vice President, Regulatory Affairs, who
Actived: 6 days ago
Oculis Oculis Announces Completion of Enrollment in Phase 2
WebTopline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON) Oculis also aims to complete an IND submission for OCS-05 in the U.S. in 2024 OCS-05 has been granted orphan drug designation in the United States
Oculis Oculis Announces First Patient First Visit in Phase 2b …
WebLicaminlimab is a novel anti-TNFα biologic eye drop with an established dual mechanism of action, anti-inflammatory and anti-apoptotic, and a potential transformative impact on the treatment of inflammatory eye diseases; RELIEF Phase 2b trial will evaluate the efficacy and safety of licaminlimab in moderate-to-severe Dry Eye Disease, and …
Oculis Strengthens Pipeline by In-Licensing Neuroprotective Drug
WebFirst-in-class peptidomimetic with distinct MoA activating trophic signaling pathways to protect and prevent damage to the optic nerve and retina Potential to be disease modifying in lead indications such as glaucoma, geographic atrophy, acute optic neuritis (AON) and other optic neuropathies Proof
Oculis Oculis announces publication of Ph2 data showing topical …
WebPositive Phase 2 data, published in Clinical Ophthalmology, highlights the potential of licaminlimab to become a novel treatment in DED Primary and secondary efficacy endpoints were successfully met and showed superiority of licaminlimab over vehicle for the relief of ocular discomfort in patients with severe DED
Oculis to Present at Bank of America Global Healthcare Conference
WebZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the Bank of …
Oculis Oculis Announces Patient Dosing in its First Phase 3 with …
Web• OCS-01 has demonstrated efficacy and safety in a Phase 2b clinical trial in DME offering the potential to become the first topical eye drop and non-invasive treatment for DME • Following a positive End-of-Phase 2 meeting with FDA, Oculis started its first Phase 3 study (DIAMOND Trial) of OCS-01
Oculis Oculis completes patient recruitment for stage 1 of Phase …
WebOculis has completed enrollment for stage 1 of its Phase 3 DIAMOND study to evaluate the efficacy and safety of OCS-01 in DME; The study will measure standard DME endpoints, such as mean change in BCVA ETDRS letters score and in macular thickness (CST, central subfield thickness) compared to baseline
Oculis Oculis Appoints Dr. Joanne Chang as Global Chief Medical
Web• Dr. J. Chang, former Novartis Global Medical Affairs Head, Ophthalmology, to lead the advancement and expansion of Oculis’ pipeline development and global portfolio management • Dr. J. Chang to be the first Oculis Global Officer based in China with the opening of a Hong Kong office, extending
Oculis appoints Dr. Frédéric Pilotaz as VP of Technology
WebLAUSANNE, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announces the appointment of Frédéric Pilotaz, PharmD, as Vice President of Technology & Pharmaceutical Sciences.
Oculis Oculis announces publication of positive Phase 2 data in
WebPositive data show topical anti-TNFα agent Licaminlimab eye drops reduced inflammation in Acute Anterior Uveitis (AAU), meeting the study’s primary efficacy endpoint Peer-reviewed paper highlights potential of Licaminlimab to become a novel non-steroidal topical treatment in anterior uveitis
Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
WebMarch 16, 2023 at 9:46 AM EDT. PDF Version. Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval. If approved, OCS-01 has the potential to become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.
Oculis appoints Dr. Frédéric Pilotaz as VP of Technology
WebBurns McClellan John Grimaldi 212-213-0006 x362 [email protected] Media relations Burns McClellan Ryo Imai / Robert Flamm 212-213-0006 x315 / 212-213-0006 x364
Oculis Oculis Announces Positive Data from Two Proof-of …
WebPositive Phase 2a data, presented for the first time, highlights the potential of OCS-02 to become a new treatment in moderate to severe DED and potentially the first personalized therapy in this disease Data also highlight the opportunity for OCS-02 to become a novel non-steroidal
Oculis Oculis announces publication of Phase 2 data showing …
WebPositive Phase 2 data, published in journal ACTA, provides the first proof-of-concept for a topical drug effect in diabetic macular edema (DME) Dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with
Oculis SEC Filing
WebUnmet needs and substantial rise in visual impairments Underpinning demand for ophthalmic innovations Driven by three key areas: A growing At least 2.2 billion people Retina $22+bn have a vision impairment, and (1) of these, at least 1 billion Market ~196m (1) people have a vision with age-related ~146m impairment that could have …
Top Categories
Popular Searched
› College or university for health care professionals in san diego ca
› How do i get individual health care
› Va health professional scholarship program
› Psychiatric mental health certification board
› Cherry health case management
› South central mental health care
Recently Searched
› Capstone health care estates at veterans
› Pediatric oral health services
› Icici lombard health insurance usa
› 6 best healthy overnight oats
› Navihealth support phone number